Nothing said here yet.
to join the conversation.
| Alan Armstrong | Buy | $8.0K | Fri, Mar 27 | Tue, Jul 21 |
| Terri A. Sewell | Sell | $8.0K | Wed, Mar 25 | Thu, Mar 26 |
For questions about this article or underlying research, email [email protected].
In Q3, GE HealthCare reported notable growth in PDx, a segment it moved to strengthen earlier this month with the $945m acquisition of SOFIE Biosciences.
GE HealthCare Technologies (NASDAQ:GEHC) reported third-quarter 2026 revenue growth across all of its business segments, supported by demand in imaging and pharmaceutical diagnostics, improved execution in patient care products and margin expansion.
Shares of healthcare technology company GE HealthCare Technologies (NASDAQ:GEHC) jumped 7.2% in the morning session after the company delivered third-quarter 2026 financial results that exceeded its expectations and raised its full-year guidance.
GE HealthCare points to broad-based growth across all three of its business divisions as its raises annual guidance.
CHICAGO (AP) — CHICAGO (AP) — GE HealthCare Technologies Inc. (GEHC) on Wednesday reported third-quarter profit of $615 million.
GE HealthCare Technologies (NasdaqGS:GEHC) reported robust Q3 performance alongside updates on its molecular imaging and ultrasound portfolio.
Moby summary of GE HealthCare Technologies Inc.'s Q3 2026 earnings call
Backlog surged 12% to $23.7 billion on imaging and diagnostics demand.
GE HealthCare's Q3 earnings and revenues beat estimates on strong segment growth and higher margins, driving raised 2026 guidance as shares gain 8.3%.
GE HealthCare Technologies (NASDAQ:GEHC) shares gained more than 4% in pre-market trading on Wednesday after the medical technology company reported third-quarter 2026 earnings and revenue above analyst expectations and raised its full-year financial outlook.
GE HealthCare separated from General Electric and began trading under GEHC in 2023.